Level Biotechnology Inc. (TPEX:3118)
Taiwan
· Delayed Price · Currency is TWD 33.25
0.00 (0.00%)
At close: Mar 10, 2026
Level Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 79.7 | 64.81 | 62.91 | 58.47 | 68.18 | Upgrade
|
| Depreciation & Amortization | 22.46 | 21.22 | 19.72 | 19.5 | 19.79 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0 | -0.02 | -0.1 | -0.08 | 0.13 | Upgrade
|
| Loss (Gain) From Sale of Investments | -8.22 | - | - | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | -0.03 | -0.06 | 0.24 | - | - | Upgrade
|
| Other Operating Activities | 1.19 | -0.19 | 2 | -3.7 | 1.37 | Upgrade
|
| Change in Accounts Receivable | -42.71 | -2 | 6.5 | -22.98 | 56.35 | Upgrade
|
| Change in Inventory | -17.51 | -9.24 | -15.39 | -17.53 | 7.36 | Upgrade
|
| Change in Accounts Payable | 14.77 | 2.55 | -14.8 | 17.36 | -25.79 | Upgrade
|
| Change in Unearned Revenue | 0.93 | -1.11 | 3.21 | 23.04 | 18.53 | Upgrade
|
| Change in Other Net Operating Assets | 9.04 | -11.86 | 5.91 | -9 | 10.03 | Upgrade
|
| Operating Cash Flow | 59.61 | 64.1 | 70.21 | 65.07 | 155.95 | Upgrade
|
| Operating Cash Flow Growth | -7.00% | -8.71% | 7.90% | -58.27% | 87.38% | Upgrade
|
| Capital Expenditures | -32.67 | -223.68 | -7.67 | -6.74 | -9.16 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.03 | 0.23 | 0.15 | - | Upgrade
|
| Investment in Securities | -2.18 | - | - | - | - | Upgrade
|
| Other Investing Activities | -4.09 | 7.54 | -3.46 | -3.6 | 0.37 | Upgrade
|
| Investing Cash Flow | -38.93 | -216.11 | -10.9 | -10.19 | -8.79 | Upgrade
|
| Long-Term Debt Repaid | -4.7 | -4.57 | -3.12 | -2.69 | -2.66 | Upgrade
|
| Net Debt Issued (Repaid) | -4.7 | -4.57 | -3.12 | -2.69 | -2.66 | Upgrade
|
| Common Dividends Paid | -58.42 | -55.17 | -55.17 | -61.66 | -51.93 | Upgrade
|
| Other Financing Activities | - | -2.88 | 2.88 | - | 0.06 | Upgrade
|
| Financing Cash Flow | -63.12 | -62.62 | -55.4 | -64.35 | -54.52 | Upgrade
|
| Net Cash Flow | -42.44 | -214.62 | 3.91 | -9.46 | 92.64 | Upgrade
|
| Free Cash Flow | 26.94 | -159.58 | 62.54 | 58.33 | 146.8 | Upgrade
|
| Free Cash Flow Growth | - | - | 7.22% | -60.26% | 81.93% | Upgrade
|
| Free Cash Flow Margin | 3.66% | -21.82% | 9.47% | 9.84% | 21.67% | Upgrade
|
| Free Cash Flow Per Share | 0.82 | -4.89 | 1.92 | 1.79 | 4.49 | Upgrade
|
| Cash Interest Paid | 0.2 | 0.28 | 0.33 | 0.35 | 0.38 | Upgrade
|
| Cash Income Tax Paid | 16.61 | 16.26 | 13.74 | 17.91 | 15.35 | Upgrade
|
| Levered Free Cash Flow | 6.06 | -175.08 | 40.7 | 40.94 | 127.71 | Upgrade
|
| Unlevered Free Cash Flow | 6.19 | -174.9 | 40.91 | 41.15 | 127.95 | Upgrade
|
| Change in Working Capital | -35.48 | -21.66 | -14.56 | -9.11 | 66.48 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.